PTO/SB/08a (05-07)
Approved for use through 09/30/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number		10550760		
Filing Date		2005-09-27		
First Named Inventor	Ander	rs Ljunggren		
Art Unit		1614		
Examiner Name	Timot	hy P. Thomas		
Attorney Docket Number	er	133087.09001		
	Filing Date First Named Inventor Art Unit Examiner Name	Filing Date First Named Inventor Ander Art Unit		

U.S.PATENTS Remove											
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	Name of Pate of cited Docu	Pages,Columns,Lines where Relevant Passages or Relevar Figures Appear				
	1	5266583		1993-11	I-30	Ohtawa					
	2	5968982		1999-10)-19	Voss et al.					
If you wish to add additional U.S. Patent citation information please click the Add button.											
U.S.PATENT APPLICATION PUBLICATIONS Remove											
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	ation	Name of Pate of cited Docu	entee or Applicant ment	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wis	h to ac	dd additional U.S. Publi	shed Ap	plication	n citatio	n information p	lease click the Add	d buttor	ı. Add		
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i		Kind Code ⁴	Publication Date	Name of Patented Applicant of cited Document	e or	where Rele	or Relevant	T 5
	1	0459136	EP			1991-12-04	Takeda Chemical Industries, Ltd.				
	2	0002543	wo			2000-01-20	Novartis-Erfindunge Verwaltungsgesells MBH				

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10550760			
Filing Date		2005-09-27			
First Named Inventor	Ander	rs Ljunggren			
Art Unit		1614			
Examiner Name	Timothy P. Thomas				
Attorney Docket Numb	er	133087.09001			

	3	01765	574	wo		2001-10-18	Novartis-Erfindungen Verwaltungsgesellschaft MBH				
	4	02400	007	WO		2002-05-23	Novartis AG				
If you wish to add additional Foreign Patent Document citation information please click the Add button Add											
NON-PATENT LITERATURE DOCUMENTS Remove											
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.									
	1	Ortlepp et al., "Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia," Eur J Pharmacol. (2002) 436(1-2):145-50.									
If you wish to add additional non-patent literature document citation information please click the Add button Add											
				EX	AMINE	R SIGNATUR	E				
Examiner Signature Date Considered											
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											
¹ See Kind Codes of USPTO Patent Documents at <u>www.USPTO.GOV</u> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.											